ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

IUG Intelligent Ultrasound Group Plc

10.00
0.50 (5.26%)
12 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Intelligent Ultrasound Group Plc LSE:IUG London Ordinary Share GB00BN791Q39 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.50 5.26% 10.00 50,045 16:35:11
Bid Price Offer Price High Price Low Price Open Price
8.50 9.50 9.50 9.00 9.50
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Electromedical Apparatus 10.1M -2.98M -0.0091 -9.89 29.42M
Last Trade Time Trade Type Trade Size Trade Price Currency
16:35:11 UT 9,999 10.00 GBX

Intelligent Ultrasound (IUG) Latest News

Intelligent Ultrasound (IUG) Discussions and Chat

Intelligent Ultrasound Forums and Chat

Date Time Title Posts
13/4/202401:13Intelligent Ultrasound. Clinical AI software420
26/4/202309:27Intelligent Ultrasound Group113

Add a New Thread

Intelligent Ultrasound (IUG) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2024-04-12 15:35:1110.009,999999.90UT
2024-04-12 15:13:369.2010,000920.00O
2024-04-12 15:13:358.50312.64O
2024-04-12 15:13:339.50151.43O
2024-04-12 15:13:169.005,000450.00O

Intelligent Ultrasound (IUG) Top Chat Posts

Top Posts
Posted at 12/4/2024 09:20 by Intelligent Ultrasound Daily Update
Intelligent Ultrasound Group Plc is listed in the Electromedical Apparatus sector of the London Stock Exchange with ticker IUG. The last closing price for Intelligent Ultrasound was 9.50p.
Intelligent Ultrasound currently has 326,869,921 shares in issue. The market capitalisation of Intelligent Ultrasound is £29,418,293.
Intelligent Ultrasound has a price to earnings ratio (PE ratio) of -9.89.
This morning IUG shares opened at 9.50p
Posted at 13/4/2024 01:13 by 40 fathoms
A charge has been registered by HSBC at Companies House. This suggest that we are in the process of obtaining some form of debt facility.

Firstly, I think it is very good news that a traditional lender such as HSBC sees us as creditworthy and we have clearly been able to demonstrate to them a repayment ability. At very least we will have had to demonstrate to cash flow positivity in the near term.

Secondly, although cash flow positivity is close at hand it will take 12 to 18 months to get to the position where we are generating sufficient levels of free cash flow to allow meaningful new investment in the business. It seems sensible to me that we would give ourselves the flexibility to accelerate investment in to the development portfolio including liver and fetalcheck and/or in to additional sales resources. The alternative would be to delay these type of investments by 12 to 18 months until the cash flows allowed it.

While we still need to see the size and terms of the facility as this is HSBC they are likely to be sensible. I think this may well mark the transition of IUG from a start up to an established business.
Posted at 08/4/2024 00:45 by 40 fathoms
This news all but confirms, that at least on a run rate basis, we should reach cash flow positivity this year and should be meaningfully cash flow positive next year.

Once this is confirmed, from a share price perspective, I think we enter a different paradigm.

Breakeven seems to be between 16 & 17 million. The way I look at FY25 is that if we assume 10% growth in simulation sales in to FY2025 and the anticipated GE royalty revenue that takes up to breakeven. Any revenue from ScanNav PNB, Needletrainer, FetalCheck, Gestational Age & Military applications in RA will all fall to the bottom line. It is probably too early for liver products to have any impact but that has the potential to be very significant indeed, especially in light of Madrigals FDA approval of a first in class NASH drug and a encouraging results from a host of others who are one or two years behind them.
Posted at 23/3/2024 01:13 by 40 fathoms
Bamboo@ There are many positive qualities I like about IUG but one of the things that I like the me most is that they are always upgrading and adding functionality to their product range. For a small company with limited resources they do this incredibly well. I have no doubt if they get this product to market, some of the possible features you suggest and more will be added overtime.
Posted at 19/3/2024 00:23 by gsbmba99
Interactive Investor article featuring IUG as one of five AIM growth shares for an ISA.
Posted at 12/3/2024 23:38 by 40 fathoms
@bamboo - Well found. So if we take some function of this price as a proxy for our clinical AI business, we can then use some function of Surgical Science P/E for our simulation business you are going to end up with a share price at @50p per share.

Given how awful AIM is at the moment at assigning value to growth companies, by my reckoning if we receive a T/O offer this year it will be at between 20p and 25p per share. If we see decent GA licensing activity you can bump that up by 5p, proof of concept in liver another 5p (liver is worth much more but also requires significant investment) and a large DOD deal for ScanNav PNB would add 2p.

A nice return but it would still leave a great deal on the table and I would prefer to see things be allowed to play out, at very least until liver is a commercial product. The question is where does the required investment for liver come from, equity, debt, partnership ? It probably needs @GBP 3.5 million to get it through trials and to market. I would be disappointed if they issued equity so I would prefer to see debt or partnership. One would think it would be possible to raise a modest amount of sensible finance against the GE revenue stream or to find an industry partner who is prepared to finance this.

With all of that said, I think it is safe to conclude that 9.5p per share significantly undervalues the business in almost all scenarios.
Posted at 11/3/2024 14:31 by gsbmba99
There's a new 510(k) approval on the FDA website for the Voluson series. This one is for Signature 20 and Signature 18. The "Decision Summary" isn't available yet so you can't compare the changes to the previous machine. This is the first 510(k) for Signature series since January of 2022. Hopefully this will now mean IUG being offered across the complete Voluson range.
Posted at 09/2/2024 10:04 by bmcollins
@bamboo
@40f

I don't wish to sound like an echo chamber here but with that update and given the recent weakness of the share price I am a little bemused as to why there has been so little reaction, i.e. no change in the 8.5p-9p price and very few, only small trades done as well.
I guess it is better than the 10% to 20% mark-downs many AIM shares have suffered after their updates recently but I read a lot of good news in their RNS today.
I'm pretty much up to my maximum in what I'd ever put into a stock of this nature but with profitability apparently very close, GEHC & Gates foundation backing it, to me the upside looks much more likely than the downside so I'm seriously thinking about breaking one of my own rules and doubling up.
Posted at 21/12/2023 00:40 by 40 fathoms
Bamboo, Always a possibility I agree. We will be either blessed or cursed on this issue by the views of IP Group. I am hopeful they are more aligned than your typical VCT or small cap manager. Even if we were to see interest today I feel anything less than 25p would be disappointing and if our plans unfold as forecast, you can up that by 5p for every 6 months that passes.

Here are my predictions for next year.

Company hits 2023 guidance
Company reaffirms 2024 guidance of profitability on a run rate basis
Company hardens 2025 financial ambitions
Company picks up large US DoD orders for SCANNAV
We see a non-exclusive licensing of SCANNAV PNB to FUJIFILM Sonosite and Mindray
On an exclusive basis and including an upfront payment - GEHC take the Gestational Age product.
Share price surges
At between 20p and 25p per share the company undertakes a 20% placement to GE Healthcare.
Proceeds from placement are used for small bolt on M&A and to expand and accelerate internal development pipeline.
We continue Sonolyst roll out on the Volouson range
We get initial data on the NASH product in collaboration with Dundee Uni
Towards the end of next year we see the launch of one new training product probably based on the gaze technology and one new clinical product probably focused on tube placement.
Posted at 08/9/2023 01:13 by bamboo2
hi, 40F, I bought into DNL last Summer 2022 for the t/o potential and a t/o was announced 30/8/2022.

Co-incidentally, it shared the IPGroup stable with IUG, and as we know, in recent years IPGroup always seem ready to do a deal. Like IUG, DNL was too, on the cusp of becoming profitable.

The DNL share price had been 11.25, the offer was 27.5p [premium approx 150%].

I reckon if we worked on that kind of basis, we'd be in the right ball park.

IUG 11 x 150% = 27.5p

Further info...
Posted at 07/9/2023 23:15 by 40 fathoms
I think it all depends as we are prisoners to our share price. In the end any offer will be a function of share price at the time and not necessary a reflection of true value.

Assuming the companies evolution of revenue and profit comes to pass, I think an offer today would come at about 20p, this would be 30p this time next year. I think in 2025 or 2026 it starts to get interesting as you would then expect the share price to reflect the fact that we would be significantly profitable, with a clear path to GBP 10 million of annual profit and plenty of growth still to come from product development and products under development. I think then an offer would come at well north of 60p.
Intelligent Ultrasound share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock